Can Bristol-Myers Squibb’s Bold Pricing Strategy Reverse Its Fortunes?

Pharmaceutical giant Bristol-Myers Squibb is navigating turbulent waters as it implements an unconventional approach to maintain its market position. With crucial blockbuster drug patents expiring, the company has embarked on an aggressive discounting campaign, offering price reductions of up to 80% directly to patients. This dramatic move raises questions about whether it can effectively counter the downward pressure on its stock performance.

Patent Expirations Drive Unprecedented Discounts

The pharmaceutical landscape presents significant challenges for Bristol-Myers Squibb as key patents near expiration, opening the door to increased generic competition and revenue pressure. In response, the company is taking extraordinary measures through its “BMS Patient Connect” platform. Beginning January 2026, the psoriasis treatment Sotyktu will be available at more than 80% off the standard price. This follows substantial discounts already in place for the blood thinner Eliquis, where patients have been benefiting from price reductions exceeding 40%.

Chief Executive Officer Christopher Boerner emphasized the company’s commitment to “removing barriers, ensuring transparency, and lowering costs for patients.” The strategic objective focuses on driving higher sales volumes and improving treatment adherence through more affordable pricing.

Should investors sell immediately? Or is it worth buying Bristol-Myers Squibb?

Pipeline Developments Offer Glimmer of Hope

Amid these challenges, recent clinical trial results provide some positive momentum. The experimental multiple myeloma drug Iberdomide demonstrated significantly improved response rates in the EXCALIBER-RRMM Phase 3 study. This development positions the treatment as a potential future blockbuster that could help offset revenue declines from patent expirations.

Market Performance and Analyst Sentiment

Despite a recent uptick of 1.64% on Friday, Bristol-Myers Squibb shares remain under substantial pressure. Technical indicators reveal the stock is trading approximately 35% below its 52-week high and has declined more than 30% since the beginning of the year. Market experts maintain a cautious stance, with the consensus rating holding at “Hold” and an average price target of $56.38.

The critical question facing investors is whether these radical price reductions combined with promising pipeline developments can successfully reverse the current downward trajectory. All eyes will be on the quarterly earnings report scheduled for October 30, which may provide clearer indications of the strategy’s effectiveness.